2. Metabolic Enzyme/Protease
  3. Drug Metabolite Cytochrome P450
  4. 931402-35-6

931402-35-6

Amatuximab Chemical Structure

931402-35-6

Chemical Structure

  • Amatuximab
  • Synonym(s): MORab-009
  • CAS No: 931402-35-6
  • InChIKey: VNWKTOKETHGBQD-UHFFFAOYSA-N
  • SMILES: [Amatuximab]

Biological Activity: Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium[1][2].

Cat. No. Product Name Purity Description
HY-B0106A Etiracetam 99.91% Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).
HY-B0106AR Etiracetam (Standard) ≥98% Etiracetam (Standard) is the analytical standard of Etiracetam. This product is intended for research and analytical applications. Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).
HY-B0106AS Etiracetam-d3 Etiracetam-d3 is the deuterium labeled Etiracetam. Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).

References

[1]. Hassan R, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927-5936. [Content Brief]
[2]. Baldo P, et al. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337-5353. Published 2017 Nov 8. [Content Brief]

Keywords:

Amatuximab